PGI5: HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHN'S DISEASE  by Ericsson, K et al.
Abstracts 123
ferences between responders in the treatment groups pro-
vides a more comprehensive characterization of the
treatment effect.
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BACKGROUND: Economic aspects are important when
assessing the overall benefit of a treatment strategy. The
number of investigations of these aspects are few within
the field of Crohn’s disease (CD). OBJECTIVE: To assess
the economic consequences, from a health care budget
perspective, of treating CD patients with budesonide CIR
(Entocort capsules) 6 mg per day as maintenance therapy
compared to no maintenance treatment (NMT). METHOD:
A validated decision-analytic model (Noble et al., 1998)
on the treatment of CD in Sweden was used. The model
used pooled patient data from randomised, double blind
trials of budesonide CIR capsules (n  90) versus placebo
(n  90) and covers a study period of one year. For
events not investigated in the clinical trials, literature and
panel data were used. Cost inputs for health care re-
sources were based on costs observed for 11 regional hos-
pitals in Sweden in year 1996. The analysis took into ac-
count costs for health care resources associated with
managing inactive and active phases of CD, e.g., diagnos-
tic and surgical procedures, physician visits, hospitalisa-
tions and drug consumption. Panel data and cost inputs
were tested in a sensitivity analysis. RESULT: Average
annual cost per patient was SEK 36,745 for budesonide
CIR capsules patients compared to SEK 38,130 for NMT
patients. With a Swedish prevalence between 13,000 to
18,000 patients this could mean annual savings of 18 to
25 million SEK (2–2.8 million USD). Stability of the re-
sults was confirmed when altering values on panel data
and cost inputs. CONCLUSION: Budesonide CIR capsules,
prolonging time in remission, is a cost-saving treatment
strategy for the treatment of Crohn’s disease in Sweden.
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OBJECTIVES: Helicobacter pylori (H.pylori) eradication
triple therapy with a combination of lansoprazole, amox-
icillin, and clarithromycin was approved in September
2000 in Japan. The objective of this analysis was to com-
pare the cost-effectiveness of this eradication therapy
with conventional H2RA therapy in Japan. METHODS:
We used decision analysis software to establish two
Markov models, one for gastric ulcers and the other for
duodenal ulcers. The model design was based on the Jap-
anese H. pylori eradication guideline and specialists opin-
ions. The model input data were derived mainly from a
literature review. The models predict the direct medical
costs, number of disease free days (DFDs) and cost per
DFD for five years. Sensitivity analyses were conducted
by varying the success rate and the probability of endo-
scopic relapse in symptomatic patients. The payer’s per-
spective was selected. RESULTS: According to the gastric
ulcer model, the expected total costs of eradication and
conventional therapies for an individual patient at the
end of five years would be 169,719 Yen and 390,921
Yen, respectively; the expected DFDs 1,454 days and
1,313 days, respectively; and the expected cost per DFD
117 Yen and 298 Yen, respectively. According to the
duodenal ulcer model, the expected total costs of the
eradication and conventional therapies would be 134,786
Yen and 324,689 Yen, respectively; the expected DFDs
1,503 days and 1,387 days, respectively; and the ex-
pected cost per DFD 90 Yen and 234 Yen, respectively.
The sensitivity analyses showed the results of baseline
analysis to be robust. CONCLUSIONS: We found that
this eradication therapy is less costly and more effective
than conventional therapy for the treatment of gastric
and duodenal ulcers in a Japanese medical setting. Thus,
eradication therapy is recommended for gastric and
duodenal ulcers from an economic as well as a clinical
viewpoint, in Japan.
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OBJECTIVE: To assess the economic outcome, from a
health care budget perspective, of treating Crohn’s dis-
ease (CD) patients with budesonide controlled ileal re-
lease (CIR) 6 mg per day as maintenance therapy com-
pared to no maintenance therapy (NMT). METHODS: A
validated decision-analytic model (Noble et al., 1998) on
the treatment of (CD) was used. The model was adjusted
to specifically depict CD patient management in Finland.
The analysis was based on pooled patient data from ran-
domised, double blind clinical trials comparing budes-
onide CIR (n  90) in maintenance therapy with placebo
(n  90). In accordance with the clinical trials the analy-
sis covered a study period of up to one year. The analysis
took into account clinical outcomes and consequences of
